By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) released its 2024 financial report, recording RMB 27.985 billion (USD 3.86 billion) in revenues, a 22.63% year-on-year (YOY) increase. The net profit attributable to shareholders of the listed company was RMB 6.337 billion (USD 873.7 million), up 47.28% YOY. Sales of innovative drugs reached RMB 13.892 billion (USD 1.9 billion), reflecting a 30.6% expansion.
Innovative Drug Achievements
In 2024, Hengrui achieved nine major innovative milestones, including marketing approvals for four Category 1 drugs: Aisute (tegileridine), Andajing (vunakizumab), Aixinan (recaticimab), and Aisuda (ivarmacitinib). Additionally, the company secured five indication approvals for fluzoparib (ovarian and breast cancer), apatinib (breast cancer), henagliflozin (diabetes), and tegileridine (postoperative moderate to severe pain).
Future Pipeline
Hengrui is poised for continued growth with 11, 13, and 23 new drugs/indications expected to gain marketing approval in 2025, 2026, and 2027 respectively, underscoring its commitment to innovation and expanding therapeutic coverage.-Fineline Info & Tech